All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
Diabetes, obesity & metabolism/Diabetes, obesity and metabolism